新基因组学
NEO
16.65
-0.60
-3.48%
新基因组学
US · NEO
#2660 按市值排名
上市于 1970
16.65
-0.60
-3.48%
实时 - 追踪5344个代码 - 心跳于386秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例下降了0.8个百分点。
机构持股
- 机构持股比例
- 113.88% -0.79pp
- 机构数量
- 308 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund91.03%
Hedge Fund18.52%
Public Company2.33%
Individual/Insider2.14%
Government Pension Fund1.14%
Private Company0.57%
Insurance Company0.15%
主要股东 截至 2026-06-30
BlackRock
16.24% · 20.87M 股
First Light Asset Management, LLC
9.56% · 12.28M 股
First Trust Advisors L.P.
7.87% · 10.11M 股
Greenhouse Funds LLLP
6.67% · 8.57M 股
Vanguard Portfolio Management, LLC
6.27% · 8.06M 股
Vanguard Capital Management, LLC
5.16% · 6.63M 股
State Street Global Advisors
4.17% · 5.36M 股
Macquarie Investment Management Business Trust
3.92% · 5.04M 股
Braidwell LP
3.83% · 4.92M 股
Schroder Investment Management North America Inc.
3.38% · 4.34M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 33次买入 · 15次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Christopher Smith | Chief Executive Officer | 0.58% |
| Jeffrey Sherman | Chief Financial Officer | 0.17% |
| Melody Harris | President of Enterprise Operations | 0.14% |
| Warren Stone | President of Clinical Division | 0.14% |
| Anthony Zook | Independent Director | 0.12% |
| Alison Hannah | Member of Scientific Advisory Board & Independent Director | 0.10% |
| Lynn Tetrault | Independent Chairperson | 0.07% |
| Alicia Olivo | General Counsel | 0.07% |
| Stephen Kanovsky | Independent Director | 0.06% |
| Michael Kelly | Independent Director | 0.06% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-30 | Warren Stone | President of Clinical Division | Derivative Exercise and Sale | -6,911 | -- |
| 2026-09-30 | Warren Stone | President of Clinical Division | Derivative Exercise and Retained | +10,651 | -- |
| 2026-08-31 | Alicia Olivo | General Counsel | Sale to Issuer | -2,692 | -- |
| 2026-08-20 | Warren Stone | President of Clinical Division | Derivative Exercise and Sale | -11,060 | -- |
| 2026-08-20 | Warren Stone | President of Clinical Division | Derivative Exercise and Retained | +17,046 | -- |
| 2026-08-03 | Gregory Aunan | Chief Accounting Officer | Open Market Disposition | -20,000 | $16.07 |
| 2026-07-29 | Jeffrey Sherman | Chief Financial Officer | Intent to Sell (Form 144) | -236,876 | $15.64 |
| 2026-06-14 | Lynn Tetrault | Independent Chairperson | Open Market Disposition | -5,307 | $11.10 |
| 2026-06-08 | Lynn Tetrault | Independent Chairperson | Open Market Disposition | -5,307 | $11.29 |
| 2026-05-31 | Michael Kelly | Independent Director | Other Derivative Acquisition | +11,069 | $10.52 |
| 2026-05-31 | Michael Kelly | Independent Director | Other Derivative Acquisition | +15,970 | -- |
| 2026-05-31 | Michael Kelly | Independent Director | Derivative Exercise and Retained | +23,077 | -- |
| 2026-05-31 | David Perez | Independent Director | Other Derivative Acquisition | +11,069 | $10.52 |
| 2026-05-31 | David Perez | Independent Director | Other Derivative Acquisition | +15,970 | -- |
| 2026-05-31 | David Perez | Independent Director | Derivative Exercise and Retained | +23,077 | -- |
| 2026-05-31 | Lynn Tetrault | Independent Chairperson | Other Derivative Acquisition | +11,069 | $10.52 |
| 2026-05-31 | Lynn Tetrault | Independent Chairperson | Other Derivative Acquisition | +15,970 | -- |
| 2026-05-31 | Lynn Tetrault | Independent Chairperson | Derivative Exercise and Retained | +23,077 | -- |
| 2026-05-31 | Felicia Williams | Independent Director | Other Derivative Acquisition | +11,069 | $10.52 |
| 2026-05-31 | Felicia Williams | Independent Director | Other Derivative Acquisition | +15,970 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
新基因组学 讨论区 0 条评论